Artificially engineered red blood cells for universal blood transfusion

被引：0

作者：

Zhang, Ying ^{[1
,3
]}

Xu, Jun ^{[2
]}

Wang, Ben ^{[1
,3
,4
,5
,6
,7
]}

机构：

[1] Zhejiang Univ, Affiliated Hosp 2, Key Lab Canc Prevent & Intervent, Canc Inst,Sch Med,China Natl Minis Educ, Hangzhou 310009, Peoples R China

[2] South China Univ Technol, Sch Biol & Biol Engn, MOE Int Joint Res Lab Synthet Biol & Med, Guangzhou 510006, Peoples R China

[3] Zhejiang Univ, Inst Translat Med, Hangzhou 310029, Peoples R China

[4] State Key Lab Transvasc Implantat Devices, Hangzhou 310009, Peoples R China

[5] Zhejiang Key Lab Frontier Med Res Canc Metab, Hangzhou 310029, Peoples R China

[6] Zhejiang Univ, Inst Fundamental & Transdisciplinary Res, Hangzhou 310058, Peoples R China

[7] Zhejiang Univ, Canc Ctr, Hangzhou 310029, Peoples R China

来源：

MATTER | 2025年 / 8卷 / 02期

基金：

中国国家自然科学基金;

关键词：

D O I：

10.1016/j.matt.2024.11.029

中图分类号：

T [工业技术];

学科分类号：

08 ;

摘要：

Artificially engineered red blood cells with immunological inertia are promising candidates for universal blood transfusions, eliminating the need to consider blood types. Their unique resilience is particularly beneficial for mismatched blood transfusions. A recent study published in the Proceedings of the National Academy of Sciences of The United States of America by Lei et al. introduced a cell silicification strategy designed to shield the blood group antigens of red blood cells, protecting them from external stressors. This approach supports biocompatible allogeneic transfusions and mechanical perfusion. The silicified red blood cells exhibited significant potential for cross-species blood transfusion without triggering immune activation.

引用

页数：3